Boston University School of Public Health, Boston, MA 02118, USA.
Clin Nutr. 2011 Dec;30(6):702-7. doi: 10.1016/j.clnu.2011.08.013. Epub 2011 Sep 29.
BACKGROUND &AIM: n-3 PUFA has been shown to decrease the risk of several components of the metabolic syndrome; however, the role of n-3 PUFA on glucose metabolism is not clear. Our aim was to systematically review the effect of n-3 PUFA on IS by conducting a meta-analysis of available RCTs.
We followed the guidelines of Cochrane's review of systematic interventions. We searched MEDLINE, EMBASE, CENTRAL and clinicaltrials.gov from the beginning of each database until October 2010. Meta-analysis was performed using a random effects model to estimate a pooled SMD and the corresponding 95% CI.
From 303 screened citations, 11 RCTs (n = 618) were eligible for inclusion in the analysis. In a pooled estimate, n-3 PUFA intervention had no effects on IS compared to placebo (SMD 0.08, 95% CI -0.11-0.28). Similarly, n-3 PUFA had no effects on IS in sub-group analyses (Type 2 diabetes vs. other population; QUICKI and other test subgroups). In the HOMA subgroup, n-3 PUFA was associated with a statistically significant increase in IS (SMD 0.30, CI 0.03-0.58) when compared to placebo.
This meta-analysis is consistent with a lack of n-3 PUFA effects on IS.
n-3 多不饱和脂肪酸（PUFA）已被证明可降低多种代谢综合征组分的风险；然而，n-3 PUFA 对葡萄糖代谢的作用尚不清楚。我们的目的是通过对现有随机对照试验（RCT）进行荟萃分析，系统地评估 n-3 PUFA 对胰岛素敏感性（IS）的影响。
我们遵循 Cochrane 系统干预评价指南。我们检索了 MEDLINE、EMBASE、CENTRAL 和 clinicaltrials.gov，检索时间均从各数据库建库开始至 2010 年 10 月。采用随机效应模型进行荟萃分析，以估计合并标准化均数差（SMD）及其相应的 95%置信区间（CI）。
从 303 篇筛选出的文献中，有 11 项 RCT（n=618）符合纳入分析的标准。汇总估计结果显示，与安慰剂相比，n-3 PUFA 干预对 IS 没有影响（SMD 0.08，95%CI -0.11-0.28）。同样，在亚组分析中（2 型糖尿病与其他人群；QUICKI 和其他检测亚组），n-3 PUFA 对 IS 也没有影响。在 HOMA 亚组中，与安慰剂相比，n-3 PUFA 与 IS 的显著增加相关（SMD 0.30，CI 0.03-0.58）。
本荟萃分析与 n-3 PUFA 对 IS 无影响的结果一致。
